IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v14y2023i1d10.1038_s41467-023-39383-8.html
   My bibliography  Save this article

Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial

Author

Listed:
  • Manuel Rodrigues

    (Institut Curie)

  • Giulia Vanoni

    (INSERM U932, PSL Research University, Institut Curie)

  • Pierre Loap

    (Institut Curie)

  • Coraline Dubot

    (Institut Curie)

  • Eleonora Timperi

    (INSERM U932, PSL Research University, Institut Curie)

  • Mathieu Minsat

    (Institut Curie)

  • Louis Bazire

    (Institut Curie)

  • Catherine Durdux

    (Hôpital Européen Georges Pompidou, Department of Radiation Oncology)

  • Virginie Fourchotte

    (Service of Breast and Gynecologic Surgery, Institut Curie)

  • Enora Laas

    (Service of Breast and Gynecologic Surgery, Institut Curie)

  • Nicolas Pouget

    (Service of Breast and Gynecologic Surgery, Institut Curie)

  • Zahra Castel-Ajgal

    (Department of Drug Development and Innovation, Institut Curie)

  • Gregoire Marret

    (Department of Drug Development and Innovation, Institut Curie)

  • Laetitia Lesage

    (Department of Pathology Institut Curie
    Centre d’Investigation Clinique Biothérapie, Institut Curie)

  • Didier Meseure

    (Department of Pathology Institut Curie
    Centre d’Investigation Clinique Biothérapie, Institut Curie)

  • Anne Vincent-Salomon

    (Department of Pathology Institut Curie
    Centre d’Investigation Clinique Biothérapie, Institut Curie)

  • Lolita Lecompte

    (Institut Curie Bioinformatics Platform, INSERM U900, Mines ParisTech)

  • Nicolas Servant

    (Institut Curie Bioinformatics Platform, INSERM U900, Mines ParisTech)

  • Sophie Vacher

    (Pharmacogenomics Unit, Service of Genetics, Institut Curie)

  • Ivan Bieche

    (Pharmacogenomics Unit, Service of Genetics, Institut Curie)

  • Caroline Malhaire

    (Department of Radiology, Institut Curie)

  • Virginie Huchet

    (Department of Nuclear Medicine, Institut Curie)

  • Laurence Champion

    (Department of Nuclear Medicine, Institut Curie)

  • Maud Kamal

    (Department of Drug Development and Innovation, Institut Curie)

  • Sebastian Amigorena

    (INSERM U932, PSL Research University, Institut Curie)

  • Olivier Lantz

    (INSERM U932, PSL Research University, Institut Curie)

  • Marion Chevrier

    (Service of Biostatistics, Institut Curie)

  • Emanuela Romano

    (Institut Curie
    INSERM U932, PSL Research University, Institut Curie)

Abstract

Concurrent chemoradiotherapy (CRT) with blockade of the PD-1 pathway may enhance immune-mediated tumor control through increased phagocytosis, cell death, and antigen presentation. The NiCOL phase 1 trial (NCT03298893) is designed to determine the safety/tolerance profile and the recommended phase-II dose of nivolumab with and following concurrent CRT in 16 women with locally advanced cervical cancer. Secondary endpoints include objective response rate (ORR), progression free survival (PFS), disease free survival, and immune correlates of response. Three patients experience grade 3 dose-limiting toxicities. The pre-specified endpoints are met, and overall response rate is 93.8% [95%CI: 69.8–99.8%] with a 2-year PFS of 75% [95% CI: 56.5–99.5%]. Compared to patients with progressive disease (PD), progression-free (PF) subjects show a brisker stromal immune infiltrate, higher proximity of tumor-infiltrating CD3+ T cells to PD-L1+ tumor cells and of FOXP3+ T cells to proliferating CD11c+ myeloid cells. PF show higher baseline levels of PD-1 and ICOS-L on tumor-infiltrating EMRA CD4+ T cells and tumor-associated macrophages, respectively; PD instead, display enhanced PD-L1 expression on TAMs, higher peripheral frequencies of proliferating Tregs at baseline and higher PD-1 levels at week 6 post-treatment initiation on CD4 and CD8 T cell subsets. Concomitant nivolumab plus definitive CRT is safe and associated with encouraging PFS rates. Further validation in the subset of locally advanced cervical cancer displaying pre-existing, adaptive immune activation is warranted.

Suggested Citation

  • Manuel Rodrigues & Giulia Vanoni & Pierre Loap & Coraline Dubot & Eleonora Timperi & Mathieu Minsat & Louis Bazire & Catherine Durdux & Virginie Fourchotte & Enora Laas & Nicolas Pouget & Zahra Castel, 2023. "Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
  • Handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-39383-8
    DOI: 10.1038/s41467-023-39383-8
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-023-39383-8
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-023-39383-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Laurel B. Darragh & Jacob Gadwa & Tiffany T. Pham & Benjamin Court & Brooke Neupert & Nicholas A. Olimpo & Khoa Nguyen & Diemmy Nguyen & Michael W. Knitz & Maureen Hoen & Sophia Corbo & Molishree Josh, 2022. "Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    2. Alexander C. Huang & Michael A. Postow & Robert J. Orlowski & Rosemarie Mick & Bertram Bengsch & Sasikanth Manne & Wei Xu & Shannon Harmon & Josephine R. Giles & Brandon Wenz & Matthew Adamow & Debora, 2017. "T-cell invigoration to tumour burden ratio associated with anti-PD-1 response," Nature, Nature, vol. 545(7652), pages 60-65, May.
    3. Ankur Chakravarthy & Ian Reddin & Stephen Henderson & Cindy Dong & Nerissa Kirkwood & Maxmilan Jeyakumar & Daniela Rothschild Rodriguez & Natalia Gonzalez Martinez & Jacqueline McDermott & Xiaoping Su, 2022. "Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance," Nature Communications, Nature, vol. 13(1), pages 1-17, December.
    4. Irene Ischenko & Stephen D’Amico & Manisha Rao & Jinyu Li & Michael J. Hayman & Scott Powers & Oleksi Petrenko & Nancy C. Reich, 2021. "KRAS drives immune evasion in a genetic model of pancreatic cancer," Nature Communications, Nature, vol. 12(1), pages 1-15, December.
    5. Shaima’a Hamarsheh & Olaf Groß & Tilman Brummer & Robert Zeiser, 2020. "Immune modulatory effects of oncogenic KRAS in cancer," Nature Communications, Nature, vol. 11(1), pages 1-11, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jianjiao Ni & Xiaofei Wang & Lin Wu & Xinghao Ai & Qian Chu & Chengbo Han & Xiaorong Dong & Yue Zhou & Yechun Pang & Zhengfei Zhu, 2024. "Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: The multicenter SWORD phase 2 trial," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    2. Xiaoyu Liu & Yaping Zhuang & Wei Huang & Zhuozhuo Wu & Yingjie Chen & Qungang Shan & Yuefang Zhang & Zhiyuan Wu & Xiaoyi Ding & Zilong Qiu & Wenguo Cui & Zhongmin Wang, 2023. "Interventional hydrogel microsphere vaccine as an immune amplifier for activated antitumour immunity after ablation therapy," Nature Communications, Nature, vol. 14(1), pages 1-19, December.
    3. Elaine Lai-Han Leung & Run-Ze Li & Xing-Xing Fan & Lily Yan Wang & Yan Wang & Zebo Jiang & Jumin Huang & Hu-Dan Pan & Yue Fan & Hongmei Xu & Feng Wang & Haopeng Rui & Piu Wong & Hermi Sumatoh & Michae, 2023. "Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy," Nature Communications, Nature, vol. 14(1), pages 1-9, December.
    4. Qiming Zhou & Yao Peng & Fenfen Ji & Huarong Chen & Wei Kang & Lam-Shing Chan & Hongyan Gou & Yufeng Lin & Pingmei Huang & Danyu Chen & Qinyao Wei & Hao Su & Cong Liang & Xiang Zhang & Jun Yu & Chi Ch, 2023. "Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    5. Jeppe Sejerø Holm & Samuel A. Funt & Annie Borch & Kamilla Kjærgaard Munk & Anne-Mette Bjerregaard & James L. Reading & Colleen Maher & Ashley Regazzi & Phillip Wong & Hikmat Al-Ahmadie & Gopa Iyer & , 2022. "Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma," Nature Communications, Nature, vol. 13(1), pages 1-17, December.
    6. Jianming Xu & Yi Li & Qingxia Fan & Yongqian Shu & Lei Yang & Tongjian Cui & Kangsheng Gu & Min Tao & Xiuwen Wang & Chengxu Cui & Nong Xu & Juxiang Xiao & Quanli Gao & Yunpeng Liu & Tao Zhang & Yuxian, 2022. "Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    7. Meghana Pagadala & Timothy J. Sears & Victoria H. Wu & Eva Pérez-Guijarro & Hyo Kim & Andrea Castro & James V. Talwar & Cristian Gonzalez-Colin & Steven Cao & Benjamin J. Schmiedel & Shervin Goudarzi , 2023. "Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response," Nature Communications, Nature, vol. 14(1), pages 1-22, December.
    8. David J. Klinke & Audry Fernandez & Wentao Deng & Atefeh Razazan & Habibolla Latifizadeh & Anika C. Pirkey, 2022. "Data-driven learning how oncogenic gene expression locally alters heterocellular networks," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    9. Shu-Ling Chen & Chia-Ying Ho & Wei-Chun Lin & Chao-Wei Lee & Yu-Chun Chen & Jiun-Liang Chen & Hsing-Yu Chen, 2022. "The Characteristics and Mortality of Chinese Herbal Medicine Users among Newly Diagnosed Inoperable Huge Hepatocellular Carcinoma (≥10 cm) Patients: A Retrospective Cohort Study with Exploration of Co," IJERPH, MDPI, vol. 19(19), pages 1-18, September.
    10. Bei Li & Guohao Wang & Kai Miao & Aiping Zhang & Liangyu Sun & Xinwang Yu & Josh Haipeng Lei & Lisi Xie & Jie Yan & Wenxi Li & Chu-Xia Deng & Yunlu Dai, 2023. "Fueling sentinel node via reshaping cytotoxic T lymphocytes with a flex-patch for post-operative immuno-adjuvant therapy," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    11. Irma Telarovic & Carmen S. M. Yong & Lisa Kurz & Irene Vetrugno & Sabrina Reichl & Alba Sanchez Fernandez & Hung-Wei Cheng & Rona Winkler & Matthias Guckenberger & Anja Kipar & Burkhard Ludewig & Mart, 2024. "Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease," Nature Communications, Nature, vol. 15(1), pages 1-23, December.
    12. Chi Zhou & Wenxin Li & Zhenxing Liang & Xianrui Wu & Sijing Cheng & Jianhong Peng & Kaixuan Zeng & Weihao Li & Ping Lan & Xin Yang & Li Xiong & Ziwei Zeng & Xiaobin Zheng & Liang Huang & Wenhua Fan & , 2024. "Mutant KRAS-activated circATXN7 fosters tumor immunoescape by sensitizing tumor-specific T cells to activation-induced cell death," Nature Communications, Nature, vol. 15(1), pages 1-21, December.
    13. Sanjay M. Prakadan & Christopher A. Alvarez-Breckenridge & Samuel C. Markson & Albert E. Kim & Robert H. Klein & Naema Nayyar & Andrew W. Navia & Benjamin M. Kuter & Kellie E. Kolb & Ivanna Bihun & Jo, 2021. "Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases," Nature Communications, Nature, vol. 12(1), pages 1-10, December.
    14. Ghanizadeh, Mojtaba & Shariatpanahi, Seyed Peyman & Goliaei, Bahram & Rüegg, Curzio, 2021. "Mathematical modeling approach of cancer immunoediting reveals new insights in targeted-therapy and timing plan of cancer treatment," Chaos, Solitons & Fractals, Elsevier, vol. 152(C).
    15. Lena Wiedmann & Francesca De Angelis Rigotti & Nuria Vaquero-Siguero & Elisa Donato & Elisa Espinet & Iris Moll & Elisenda Alsina-Sanchis & Hanibal Bohnenberger & Elena Fernandez-Florido & Ronja Mülfa, 2023. "HAPLN1 potentiates peritoneal metastasis in pancreatic cancer," Nature Communications, Nature, vol. 14(1), pages 1-18, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-39383-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.